International Journal of Nanomedicine, Год журнала: 2025, Номер Volume 20, С. 2521 - 2553

Опубликована: Фев. 1, 2025

Exosomes (Exos) derived from human umbilical cord mesenchymal stem cells (hUC-MSCs) hold great potential for treating bronchopulmonary dysplasia (BPD); however, safety concerns and effects of intranasal administration remain unexplored. This study aimed to explore the hUC-MSCs Exos investigate efficacy bio-distribution repeated in neonatal BPD models. Characteristics were analyzed. A subcutaneous tumor formation assay using a single dose or was conducted Crl:NU-Foxn1nu mice. Vital signs, biochemical indices, pathological alterations, 18F-FDG microPET/CT analysis examined. Pulmonary pathology, three-dimensional reconstructions, ultrastructural structures, vivo ex imaging analyses, enzyme-linked immunoassay assays, reverse transcription-quantitative polymerase chain reaction analyses lung tissues all documented following administration. satisfied specifications. mice did not exhibit overt toxicity carcinogenicity after 60 days observation. Repeated effectively alleviated injuries, restored pulmonary ventilation reconstruction, recovered endothelial cell layer integrity analysis. steadily accumulated postnatal day 1 14. also interrupted epithelial-mesenchymal transition inflammation reactions As nanoscale, non-cellular therapy, an effective, noninvasive treatment BPD. approach free toxic, tumorigenic risks repaired alveolar damage while interrupting with

Язык: Английский